



Role of Advanced MRI techniques in early detection of pathological response to neo adjuvant chemotherapy in breast cancer patients

A Thesis

Submitted for the Partial Fulfilment of the Requirements of the Doctorate Degree in
Radiology

By

Abeer Hamed Abdel Hameed Ibrahim

M.B., B. Ch., M. Sc

Faculty of Medicine - Ain Shams University

Under supervision of

Prof. Dr. Maha Khaled Abdelghaffar

Professor of Radiology

Faculty of Medicine - Ain Shams University

Prof. Dr. Samer Malak Botros

Professor of Radiology

Faculty of Medicine - Ain Shams University

Dr. Amal Ibrahim Ahmed

Lecturer of Radiology

Faculty of Medicine - Ain Shams University

Faculty of Medicine
Ain Shams University
2018



First and foremost, thanks are due to Allah, the most Beneficent and Merciful.

Thanks to Prof. Dr. Maha Abdel Ghaffar, Professor of Radiodiagnosis, Faculty of Medicine-Ain Shams University, for giving me the honor to work under her supervision, judicious guidance and kind support at this study.

I wish to express my great thanks to Prof. Dr. Samer Malak, Professor of Radiodiagnosis, Faculty of medicine-Ain Shams University, for her kind assistance and guidance.

My deep appreciation Dr. Amal Ibrahim, Lecturer of Radiodiagnosis, Faculty of medicine-Ain Shams University, for her sincere guidance and effort during this study.

I am indebted to my parents, my family, my friends and my colleagues for their endless and continuous help and support.



Abeer Hamed

LIST OF CONTENTS

List of Abbreviations.....	II
List of Figures and Tables	III
Introduction and Aim of work.....	1
Review of literature.....	4
Radiological anatomy of breast.....	4
Pathology of breast cancer and pathological basis of neo-adjuvant chemotherapy treatment assessment	23
Imaging technique and image interpretation	42
Patients and Methods.....	86
Results.....	94
Illustrative cases.....	
Discussion.....	127
Summary and Conclusion	134
Future Implications	137
References	138
Arabic Summary	-

LIST OF ABBREVIATIONS

ADC	Apparent Diffusion Coefficient
ALNs	Axillary Lymph Nodes
AMF	Anterior Mammary Fascia (AMF)
ASL	Anterior Suspensory Ligament (ASL)
BIRADS	Breast Imaging Reporting and Data System
BRCA1	Breast Cancer Gene 1
BRCA2	Breast Cancer Gene 2
CT	Computed Tomography
CR	Complete Response
CTH	Chemotherapy
DEC	Dynamic Enhanced Contrast
DCIS	Ductal Carcinoma in Situ
DWI	Diffusion Weighted Image
ER	Estrogen Receptor
FN	False Negative
FP	False Positive
HER2	Human Epidermal Growth Factor Receptor 2
IDC	Invasive Ductal Carcinoma
IDC-NST	Invasive Ductal Carcinoma- Non Specific Type
ILC	Invasive Lobular Carcinoma
LCIS	Lobular Carcinoma In Situ
LN	Lymph Node
LIQ	Lower Inner Quadrant
LOQ	Lower Outer Quadrant
Ki-67	Profilteartive Factor
MIP	Maximum Intensity Projection
MLH1	MutL Homolog 1
MLH2	MutL Homolog 2
MR	Magnetic Resonance
MRS	Magnetic Resonance Spectroscopy
NAC	Neo Adjuvant Chemotherapy
NACT	Neo-Adjuvant Chemo Therapy
NME	Nonmass Enhancement
NOS	Not Otherwise Specified

NST	Non Specific Type
OCL	O'clock
pCR	Pathological Complete Response
PMF	Posterior Mammary Fascia
PPM	Parts Per Million
PPV	Positive Predictive Value
PR	Progesterone Receptor
PR	Partial Response
PSL	Posterior Suspensory Ligament
PTEN	Phosphatase and Tensin Homolog
PD	Progressive Disease
PRESS	Point-Resolved Spectroscopy Sequence
RECIST	Response Evaluation Criteria In Solid Tumors
Resp.	Response
RCR	RCR Radiological Complete Response
T	Tesla
TP	Total Positive
SNR	Signal to Noise Ratio
SD	Stable Disease
STK11	Serine/Threonine Kinase 11
SV MRS	Single Voxel Magnetic Resonance Spectroscopy
tCho	Total Choline
TDLU	Terminal Ductal Lobular Unit
TN	True Negative
TP	True Positive
TP53	Tumor Protein 53
UOQ	Upper Outer Quadrant
VOI	Volume-of-Interest
WI	Weighted image

LIST OF FIGURES

Fig. no.	Title	Page no.
1	Component of the breast	4
2	Breast zonal anatomy	6
3	Classification of the microstructure of the breast	6
4	physiologic enhancement of the nipple by MR.....	7
5	Diagram of segmental breast anatomy	8
6	MR assessing invasion of the pectoral fascia and pectoral musculature	9
7	Anatomical and surgical anatomy of axillary lymph nodes.....	10
8	Axial T1 weighted imaging breast MRI.....	11
9	Axial T2 weighted images of both breasts	12
10	Nipples enhancement on MRI.....	12
11	Post contrast T1 in 1st week of menstrual cycle	14
12	Lymph node in the posterior medial breast.....	14
13	Table containing risk factors for breast cancer	16
14	Intra-ductal carcinoma.....	16
15	(a) Noncomedo DCIS and (b) Cribriform DCIS.....	17
16	Infiltrating ductal carcinoma of breast	18
17	Invasive lobular carcinoma	20
18	Mucinous (colloid) carcinoma	21
19	Medullary carcinoma, (a) gross specimen and (b) microscopic.....	21
20	Paget disease of the breast.....	22
21	Table containing TNM classification.....	22
22	Microscopic picture of metastatic residual carcinoma	27

Fig. no.	Title	Page no.
	in a lymph node	
23	Partial response in palpable breast lesion.....	46
24	Breast MR images prior and post neo adjuvant chemotherapy, with complete response	48
25	MRS of a patient with papillary breast carcinoma.....	49
26	Misregistration artifact	52
27	Inhomogeneous fat saturation	55
28	Sagittal MIP image shows normal nipple enhancement ...	59
29	MRI Enhancement pattern	60
30	Table Summarizing recent 2018 BIRAD criteria.....	73
31	Diagrammatic representation of BIRADS classification.....	74
32	A table illustrating RECIST module for assessment of treatment response	74
33	MIP of a patient showing complete pathological response	76
34	Represents the change of ADC value during treatment.....	77
35	Table showing Clinical variables for patients.....	79
36	Table showing the Correlation between size response and over all radiological response.....	80
37	A column chart showing relation between treatment response according to size and over all radiological response	83
38	Table showing the Correlation between size response and pathological response	85
39	A column chart showing relation between treatment response according to size and pathological	97

Fig. no.	Title	Page no.
	treatment response.....	
40	Table showing the Correlation between ADC response and over all radiological response.....	99
41	A column chart showing relation between treatment response according to ADC value change and radiological treatment response.....	107
42	A table showing the Correlation between ADC response and pathological response	109
43	A column chart showing relation between treatment response according to ADC value change and pathological treatment response.....	111
44	A table showing the correlation between Choline peak response and over all radiological response	113
45	A table showing the correlation between Choline peak response and over all radiological response	115
46	A table showing the Correlation between Choline peak response and pathological response.....	117
47	A column chart showing relation between treatment response according to choline peak change and pathological treatment response.....	119
48	A table showing the Correlation between nodal response and over all radiological response.....	121
49	A column chart showing relation between nodal treatment response and radiological treatment response.....	123
50	A table showing the Correlation between nodal response and pathological response	125
51	A column chart showing relation between nodal treatment response and pathological treatment	

Fig. no.	Title	Page no.
	response	
52	A table showing the Correlating over all radiological response with pathological response	
53	A column chart showing relation over all radiological response and pathological response	
54	A table summarizing pre and post CTH MRI findings.....	
55	Base line MRI study for a patient(A) MIP, (b) MRS images.....	
56	A patient T1 post contrast (a) pre CTH and (b) post CTH showing no response according to RECIST criteria.....	
57	measuring ADC value for a patient (a) pre & (b) and post CTH	
58	T1 WI of a patient (a) pre CTH and (b), Post CTH, with regressive response.....	
59	A patient (a)axial images CT lung, (b) axial CT images of the abdomen showing metastasis.....	
60	A table summarizing pre and post CTH MRI findings for case 2	
61	T1 post contrast fat suppressed images of the lesion (A) pre CTH & (B) post CTH	
62	measuring ADC value of the lesion pre (A) and post CTH (B).....	
63	A table summarizing pre and post CTH MRI findings for case 3	
64	A patient images (a) pre CTH MRS study & (b) subtracted T1 WI images post contrast	
65	A and B: Lesion pre and post CTH MIP images	

Fig. no.	Title	Page no.
	showing remarkable regression.....	
66	A table summarizing pre and post CTH MRI findings for case 4	
67	Base line study of a patient, pre CTH T1WI & post contrast MIP	
68	ADC map an DWI of the lesion, on pre CTH.....	
69	A and B: Lesion pre and post CTH MIP images showing remarkable regression.....	
70	A table summarizing pre and post CTH MRI findings for case 5	
71	(A) and (B): pre and post CTH T1 showing total disappearance of tumoral (C) and (D) are showing resolution of axillary lymph nodes.....	
72	Measuring ADC value of a lesion (a) pre and (b) post CTH	
73	A table summarizing pre and post CTH MRI findings for case 6	
74	Choline peak of a lesion on (a) pre CTH and (b)post CTH.....	
75	showing DWI and ADC map of the lesion on post CTH study	
76	A table summarizing pre and post CTH MRI findings for case 7	
77	Choline peak of a lesion on (a) pre CTH and (b)post CTH.....	
78	T1 post contrast of a patient (A) pre CTH and (B) post CTH showing no response according to RECIST criteria.....	
79	A table summarizing pre and post CTH MRI	

Fig. no.	Title	Page no.
	findings for case 8	
80	A patient with images showing (a) pre CTH multiple sequences on MRS study, (b, c & d) the multi focal nature of the disease, note the skin edema & (e) nodal enlargement at right axilla.....	
81	DWI and ADC map of multiple lesions	
82	Patient post CTH study showing (a) multiple sequences images showing disease response to treatment on MRS study, (B and C) lymph node response and (D) mean ADC value.....	
83	A table summarizing pre and post CTH MRI findings for case 9	
84	Pre and post CTH MRS study of breast lesion	
85	post contrast T1 images with subtraction(a-f) showing pre and post CTH changes.....	
86	(A&B) Axial contrast enhanced CT images showing metastasis.....	
87	A table summarizing pre and post CTH MRI findings for case 10	
88	choline peak on (a) pre CTH, with (b) disappearance of lesion on post CTH study.....	
89	MR images of a patient, (a&b) T1 post contrast images MIP images of pre CTH and post CTH, (c&d) represent post contrast images, (e&f) T1 axial cuts.....	
90	(a, b) single voxel MRS study of the 2 breast lesions...	
91	(a) showing malignant lesion iso (b) representing the lesion sclerotic nature (c) dynamic curve was type I....	
92	DWI and ADC map of both right and left breast lesions.....	

INTRODUCTION

Neo adjuvant chemotherapy (NAC) has been increasingly utilized in the treatment of breast cancer, as the long-term distant and local-regional control of cancer provided by NAC have been reported to be similar to those offered by adjuvant chemotherapy. *(Cho et al., 2014)*

NAC was used for treatment of locally advanced breast cancer. Nowadays, NAC is more and more used in early stages of breast cancer, for example to enable breast conserving therapy (for patients who were originally scheduled for mastectomy), to enable less complicated surgery in cases where skin or pectoral muscle is involved, or to achieve better cosmetic results after surgery. *(Lobbe et al., 2012)*

Decisions regarding the continuation of current regimens and the appropriate type and timing of surgery depend on the radiological and clinical assessment of residual tumor size during neoadjuvant chemotherapy. Until now, many studies have shown that physical examinations, mammography and sonography provide suboptimal evaluations of lesion extent that do not allow accurate assessments of pathological response or residual tumor size *(Shin et al., 2011)*.

Many examinations have been proposed to evaluate response monitoring in breast cancer patients receiving NAC, such as physical examination, mammography, and ultrasound. However, their accuracy was only modest. There is increasing evidence that magnetic resonance imaging (MRI) is an excellent imaging tool to monitor response to NAC, for both early response monitoring and the assessment of residual disease extent. (**Lobbe *et al.*, 2012**)

Early response monitoring is considered to be the monitoring of disease changes after the first cycle(s) of NAC treatment. In other words, it is the assessment of disease changes before the completion of the entire course of NAC. The MRI techniques that were most frequently used were dynamic, contrast-enhanced MRI (DCE-MRI), diffusion weighted-imaging (DWI), and MR spectroscopy (MRS). (**Lobbe *et al.*, 2012**).

Standard DCE-MRI can be used for early response monitoring. In this approach, lesion morphology and extent is assessed by evaluating contrast-enhanced, T1 weighted images and by analyzing the signal-intensity time curves in the contrast-enhanced dynamic series. Measurement of tumor diameter is perhaps the simplest method of (early) response monitoring (**Kul *et al.*, 2007**).

Change of largest late enhancement diameter in the tumor on serial MRI has the potential to assess early breast cancer

response to neo adjuvant chemotherapy. In clinical practice, the MRI response prediction test may offer the oncologist an objective tool of high specificity to tailor the chemotherapy for each individual patient (**Loo *et al* , 2008**).

In breast cancer, dense packing of cells results in a restricted movement of water molecules. As a result, the ADC value decreases in DWI. During NAC, cell density of the tumor generally decreases, improving water molecule movement within the tumor. As a consequence, the ADC increases during NAC if a proper response is expected. If ADC values remain stable or even decreases further, it would be suggestive for stable or progressive disease under NAC. Thus, measurement of ADC might be a suitable parameter for evaluating treatment response. (**Woodhams *et al.*, 2010**)

In MRS, the molecular composition of a tissue of interest is analyzed by looking at the spectrum of resonances produced by the MR signal. This spectral ‘signature’ is used to diagnose certain metabolic disorders that are associated with tumour cells. Relative to normal breast tissue, breast cancers have increased levels of choline-containing compounds (**Lobbe’s *et al*, 2012**).

Some studies have shown a decrease by 100 % in the concentration of tumoral choline following 3-4 cycles of neo adjuvant chemotherapy. (**Baek *et al*, 2009**)

AIM OF THE WORK

The purpose of this study was to determine the accuracy of MRI in early detection of pathological response after 3 cycles of neo adjuvant chemotherapy for breast cancer. That will be compared with the gold standard of post-surgical pathology.